Juniper: An Open-Label Extension and Safety Monitoring Study of Patients with Moderately to Severely Active Crohn's disease Previously Enrolled in the Etrolizumab Phase III protocol GA29144

Sponsor: Genentech, Inc.

Location(s): United States


This two-part, open-label extension and safety monitoring study will examine the safety and efficacy of continued etrolizumab treatment in patients with moderate to severely active Crohn's disease who were previously enrolled in the etrolizumab Phase III Study GA29144.